Transdermal Fentanyl in Patients with Cachexia—A Scoping Review
Cancers · 05.09.2024 · 16 (17) · 3094
DOI: 10.3390/cancers16173094 ↗Kurz gefasst
Scoping Review in der Zeitschrift Cancers, online erschienen am 05.09.2024. Verfasst von Andrea Carlini und 14 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cachectic patients frequently require transdermal fentanyl (TDF) for pain management, but data on its efficacy and safety are scarce and inconsistent. This scoping review aims to analyze the evidence concerning TDF administration in patients with cachexia irrespective of the underlying pathology. The primary objective is to assess the analgesic efficacy and tolerability of TDF in cachectic patients. The secondary objective is to identify cachexia characteristics that may influence fentanyl pharmacokinetics (PK). A comprehensive search of PubMed, Embase, and Web of Science databases was conducted up to March 2024. The review included observational and clinical studies on cachectic patients with moderate to severe pain treated with TDF patches at any dosage or frequency. Phase 1 trials, animal studies, case reports, preclinical studies and conference abstracts were excluded. Nine studies were included: four studies reported that cachexia negatively impacted TDF efficacy, increasing required doses and lowering plasma concentrations; three studies found minimal or no impact of cachexia on TDF efficacy and PK; two studies suggested that cachexia might improve TDF outcomes. Study quality ranged from moderate to high, according to the National Institutes of Health (NIH) Quality Assessment Tool. The current evidence is insufficient to provide any definitive recommendations for TDF prescribing in cachectic patients.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy.
- Department of Medical and Surgical Sciences, University of Bologna, 40126 Bologna, Italy.
- Biostatistics and Clinical Trials Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
- Palliative Care Unit, Azienda Unità Sanitaria Locale (AUSL) Romagna, 47121 Forlì, Italy.
- Radiation Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, 40126 Bologna, Italy.
- Palliative Care Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori", 47014 Meldola, Italy.
ORCID-Profile: Andrea Carlini, Emanuela Scarpi, Alessio Giuseppe Morganti
Zitieren
APA
Carlini, A., Scarpi, E., Bettini, C., Ardizzoni, A., Donati, C. M., Fabbri, L., Ghetti, F., Martini, F., Ricci, M., Sansoni, E., Tenti, M. V., Morganti, A. G., Bruera, E., Maltoni, M. C., & Rossi, R. (2024). Transdermal Fentanyl in Patients with Cachexia—A Scoping Review. Cancers, 16(17), 3094. https://doi.org/10.3390/cancers16173094
Vancouver
Carlini A, Scarpi E, Bettini C, Ardizzoni A, Donati CM, Fabbri L, et al. Transdermal Fentanyl in Patients with Cachexia—A Scoping Review. Cancers. 2024;16(17):3094. doi:10.3390/cancers16173094
BibTeX
@article{Carlini2024,
author = {Carlini, Andrea and Scarpi, Emanuela and Bettini, Carla and Ardizzoni, Andrea and Donati, Costanza Maria and Fabbri, Laura and Ghetti, Francesca and Martini, Francesca and Ricci, Marianna and Sansoni, Elisabetta and Tenti, Maria Valentina and Morganti, Alessio Giuseppe and Bruera, Eduardo and Maltoni, Marco Cesare and Rossi, Romina},
title = {Transdermal Fentanyl in Patients with Cachexia—A Scoping Review},
journal = {Cancers},
year = {2024},
volume = {16},
number = {17},
pages = {3094},
doi = {10.3390/cancers16173094}
}
EUVIMED